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Introduction
Tuberculosis (TB) is one of  the infectious diseases with 
the highest morbidity and mortality in the world [1]. 
First-line treatment of  TB consists of  isoniazid, rifam-
pin, pyrazinamide and ethambutol during the first two 
months, continuing with isoniazid and rifampin for 
another four months [1]. Although treatment is often 
successful, healthcare providers around the world are 
confronted with treatment failure daily. Recently, Pasi-
panodya et al. showed that risk on treatment failure was 
almost nine fold higher in patients with low drug expo-
sure compared to patients with higher drug exposure [2]. 
Therefore, monitoring of  drug exposure in patients at 
risk for low drug exposure is worthwhile to explore in a 
prospective manner [3].
To be able to evaluate drug exposure a fast, accurate and 
simple method for determination of  isoniazid, rifamp-
in, pyrazinamide and ethambutol in serum is valuable. 
Like for other antimicrobial drugs, it would be ideal to 
determine all four compounds in the same sample using 
a single method of  analysis [4,5]. Song et al. published a 
method for the simultaneous determination of  all first-
line anti-TB drugs using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) [6]. Unfortunately, the 
polar compounds isoniazid, pyrazinamide and ethambu-
tol elute near the void volume of  the system, co-eluting 
with endogenous compounds resulting in substantial ion 
suppression [6,7]. As matrix effects may vary within and 
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RESEARCH ARTICLE
Clinical studies on tuberculosis have shown a correlation between low drug exposure and treat-
ment failure and acquired drug resistance. Objective was to develop a LC-MS/MS method for the 
quantification of  isoniazid, pyrazinamide and ethambutol. Stable isotope-labelled isoniazid-D4 
and ethambutol-D4 were used as internal standards. Protein binding of  isoniazid, pyrazinamide 
and ethambutol was investigated and proved low. Therefore, sample preparation using ultrafiltra-
tion could be applied, resulting in linear calibration curves in the range of  0.2-8 mg/L for isonia-
zid and ethambutol and 2-80 mg/L for pyrazinamide. The method was validated according to the 
guidelines of  the FDA.
A fast, simple and reliable LC-MS/MS method has been developed for the simultaneous determi-
nation of  isoniazid, pyrazinamide and ethambutol in human serum for therapeutic drug monitor-
ing and pharmacokinetic studies. 
Keywords: isoniazid, pyrazinamide, ethambutol, therapeutic drug monitoring, LC-MS/MS, tuberculosis.
* both first authors contributed equally
‡Present address: QPS Netherlands B.V., PO Box 137, 9700 AC 
Groningen, The Netherlands
STURKENBOOM MGG       J. APPL. BIOANAL
90
between subjects, ion suppression at the time of  elution 
of  the compounds of  interest should be avoided or over-
come using a stable isotope-labelled internal standard 
[8–10].
Zhou et al. used hydrophilic interaction chromatography 
(HILIC) to quantify isoniazid, rifampin, pyrazinamide, 
ethambutol and streptomycin [11]. They tested five dif-
ferent HILIC columns and several mobile phase com-
positions. An initial attempt by the authors to determine 
isoniazid and ethambutol using HILIC was abandoned, as 
our method suffered from split peaks and bad repeatabil-
ity. Recently, Kim et al. developed a LC-MS/MS method 
for the simultaneous quantification of  20 anti-TB drugs. 
The method consisted of  two different precipitation 
methods, different solid and mobile phases [12].
We successfully applied ultrafiltration as a means of  sam-
ple preparation for the polar compound ribavirin [13] 
and we were interested whether this might also be ap-
plied for the first-line anti-TB drugs. However, rifamp-
in shows high protein binding of  around 80-90% [14], 
which makes it a less suitable candidate for ultrafiltration 
compared to isoniazid, pyrazinamide and ethambutol. 
Therefore, it was decided to split the patient sample, fol-
lowed by a subsequent separate analysis of  rifampin and 
a separate one for isoniazid, pyrazinamide and ethambu-
tol together resulting in more reliable results within the 
same runtime. A previously developed method will be 
used for the analysis of  rifampin [7,15]. The objective of  
this study was to develop and validate a simple and rapid 
LC-MS/MS method for the determination of  isoniazid, 
pyrazinamide and ethambutol in human serum. 
 
Materials and methods
Chemicals, reagents and disposables
Isoniazid (purity >99%) was purchased from Bufa (Uit-
geest, The Netherlands). Ethambutol dihydrochloride 
(purity >99%) and pyrazinamide (purity ≥98%) were pur-
chased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). The internal standard isoniazid-D4 was produced 
by CDN Isotopes (Pointe-Claire, Canada). The internal 
standard ethambutol-D4 was synthesized by Syncom 
(Groningen, the Netherlands). Acetonitrile (Ultra LC-MS-
grade) was obtained from BioSolve (Valkenswaard, The 
Netherlands). Ammonium acetate and acetic acid (p.a. 
quality) from Merck were purchased from VWR (Amster-
dam, The Netherlands). Water was purified with a Mil-
li-Q system (Millipore Corporation, Billerica, MA, USA).
Blank human serum and plasma was obtained from 
healthy volunteers according to the appropriate guide-
lines of  the University Medical Center Groningen. 
Pall Nanosep 30K Omega centrifugal devices, Varian 
non-deactivated 2 mL borosilicate glass screw top vials 
and 600 μL polypropylene screw top vials were purchased 
from VWR (Amsterdam, The Netherlands). The inserts 
were made from Schott Fiolax®-clear glass and were pur-
chased from Aluglas (Uithoorn, The Netherlands). 
Equipment and conditions
Experiments were performed on an Agilent 6460A (San-
ta Clara, Ca, USA) triple quadrupole LC-MS/MS sys-
tem, with an Agilent 1200 series combined LC-system. 
The mass selective detector operated in heated electro-
spray positive ionisation mode and performed dynamic 
multiple reaction monitoring (DMRM) with unit mass 
resolution. High purity nitrogen was used for both the 
source and collision gas flows. Precursor ions, product 
ions, optimum fragmentor voltages and collision energy 
values are listed in Table 1. For all substances the capil-
lary voltage was set at 4000 V, gas temperature at 320°C, 
gas flow at 13 L/min, nebulizer gas at 60 psi, sheath gas 
temperature at 400°C, sheath gas flow at 12 L/min and 
the nozzle voltage at 0 V. The Agilent 1290 autosampler 
and the 1260 TCC column oven were set at a temperature 
of  20°C.
Separation was performed on an Atlantis T3 re-
versed-phase C18 analytical column (2.0 x 100 mm, 3 
µm particle size) from Waters (Etten-Leur, The Nether-
lands). The mobile phase consisted of  acetonitrile, water 
and a 200 mM ammonium acetate buffer pH 5.0. Chro-
matographic separation was performed using the mobile 











Ethambutol 205.1 116.1 76 13 1.15
Ethambutol-D4 209.1 120.1 76 13 1.15
Isoniazid 138.1 121.0 72 11 1.41
Isoniazid-D4 142.1 125.0 72 11 1.40
Pyrazinamide 124.0 81.0 72 20 1.72
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phase gradient listed in Table 2 at a flow of  500 μL/min, 
which resulted in a run time of  2.5 minutes.
Peak area ratios of  the analytes and their associated in-
ternal standards were used to calculate concentrations. 
Agilent Masshunter software for quantitative analy-
sis (version B.04.00) was used for quantification of  the 
analysis results. Vortexing was performed with a Labtek 
multi-tube vortexer (Christchurch, New Zealand). Cen-
trifugation was performed using a unthermostated Het-
tich EBA 21 centrifuge (Tuttlingen, Germany) with a 45º 
-fixed angle rotor. Temperature was not controlled be-
cause no effect of  increasing temperature was observed 
during earlier experiments (data not shown).
Method development
The analytical range was based on clinical pharmacoki-
netic data and set at 0.2–8 mg/L for isoniazid and etham-
butol and 2–80 mg/L for pyrazinamide [3,16]. 
As stable isotope-labelled internal standards are known 
to compensate for matrix effects [9,10], isoniazid-D4 
and ethambutol-D4 were used as such. Since a stable 
isotope-labelled internal standard for pyrazinamide was 
unavailable, no internal standard was used for the quanti-
fication of  this compound. 
I. Protein binding and ultrafiltration
Reported protein binding levels vary considerably for the 
three compounds: ranging from 0 to 74% for isoniazid 
[17,18] from 5 to 50% for pyrazinamide [17,19] and from 
10 to 30% for ethambutol [17,20]. However, one expects 
protein binding to be limited as isoniazid, pyrazinamide 
and ethambutol are very polar compounds. If  protein 
binding proves to be low, ultrafiltration as a means of  
deproteinization of  the serum samples can be applied. 
Although ultrafiltration is commonly used for determin-
ing free unbound drug levels in serum [21], it has pre-
viously been applied as a means of  sample preparation 
for other polar compounds such as acyclovir, ganciclovir, 
ribavirin and zidovudine [13,22–25]. The obtained ultra 
filtrate is purely aqueous which is particularly suitable for 
injecting onto LC-systems that are equilibrated under the 
same conditions. To investigate the applicability of  ultra-
filtration for the assay, it was decided to determine pro-
tein binding of  the three compounds using the 30 kDa 
centrifuge filters applied for the sample preparation. The 
Pall Nanosep 30 K Omega centrifugal device was cho-
sen because it removes over 99.5% of  all serum proteins, 
shows low protein binding, allows for fast processing 
times and fits standard micro-centrifuges [13].
Protein binding was determined by measuring a calibra-
tion curve with calibration standards at seven levels pre-
pared in human serum and compare it to an equivalent 
calibration curve prepared in water with added blank ul-
tra filtrate to compensate for matrix effects. The ratio of  
the slopes of  these curves shows the extent of  protein 
binding. In this experiment, calibration curve samples 
were freshly prepared and processed within 30 minutes 
to minimise alterations to isoniazid other than the revers-
ible protein binding under investigation. This period is 
comparable to other studies on protein binding [26,27]. 
Inert type 1 borosilicate glass inserts were used to mini-
mise any adsorption of  ethambutol to glass inserts. 
II. Adsorption
During early method development, a significant decline 
in signal for ethambutol was observed when the aqueous 
test mixtures were injected from the standard non-deac-
tivated glass vials compared to plastic vials. To investigate 
this observation, an adsorption test was performed. A 
test solution with isoniazid, pyrazinamide and ethambu-
tol was prepared and was divided over a polypropylene 
vial, a glass vial and a glass insert made out of  type I bo-
rosilicate glass. The samples were shaken vigorously for 
one minute and five repetitive injections were made from 
each type of  vial.
III. Carry-over
Carry-over from high isoniazid and ethambutol stan-
dards was observed during method development. There-
fore, an experiment in fivefold was performed to evaluate 
the magnitude of  the carry-over by injecting five LLOQ 
(Lower Limit of  Quantification) samples after a HLQ 
Table 2. Mobile phase gradient. 
Step Time Mobile Phase
(min) Eluent A (% v/v) Eluent B (% v/v)
0 0.00 100 0
1 0.01 90 10
2 1.20 90 10
3 1.21 0 100
4 1.35 0 100
5 1.36 100 0
6 1.50 100 0
7 1.51 0 100
8 2.00 0 100
9 2.01 100 0
10 2.50 100 0
Eluent A: 200 mM ammonium acetate buffer pH 5.0 : water (5 : 
95), Eluent B: 200 mM ammonium acetate buffer pH 5.0 : water : 
acetonitrile (5 : 45 : 50).
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(Higher Limit of  Quantification with 8.0 mg/L isoniazid 
and ethambutol and 80 mg/L pyrazinamide) sample. 
Sample preparation
For the calibration (reference) standards and Quality 
Control (QC) samples, separate stock solutions of  200 
mg/L isoniazid and ethambutol and 2000 mg/L pyrazin-
amide in water were prepared. Calibration standards and 
QC samples were freshly prepared immediately before 
use by diluting appropriate amounts of  stock solutions 
with blank human serum or plasma. QC samples were 
freshly prepared as stability of  isoniazid is known to 
be limited [28,29]. The total amount of  stock solutions 
added to the serum was less than 5% of  the final vol-
ume. Calibration standards at eight levels ranged from 
0.2-8.0 mg/L for isoniazid and ethambutol and from 
2.0-80 mg/L for pyrazinamide. QC samples consisted of  
LLOQ, Low, Medium, High and over-the-curve (OTC) 
levels for each compound (Table 3).
The internal standard solution was prepared with 0.25 
mg/L isoniazid-D4 and 0.25 mg/L ethambutol-D4 in 
water. 
QC samples for the freeze/thaw stability were prepared 
beforehand. Separate Low and High level QC samples 
in human serum were thawed, frozen and analysed on 
three consecutive days. The samples for determining the 
bench top stability were freshly prepared and analysed 
immediately and after being kept for 24 h at ambient tem-
perature. 
Calibration standards, QC or human serum samples were 
homogenised and aliquots of  10 µL were directly trans-
ferred onto the upper reservoir of  the centrifuge filters 
and 250 µL of  internal standard solution was added. The 
centrifuge filters were closed and the samples were briefly 
homogenised using a vortex mixer. Filtration was done 
by centrifugation for 10 minutes at 14000 g at an angle 
of  45º. A 5 µL volume of  the ultra filtrate was injected 
onto the LC-MS/MS system. Samples for the stability 
test were processed in the same way as the samples for 
the validation and routine analysis. 
Analytical validation
In accordance with the ‘Guidance for Industry – Bioana-
lytical Method Validation’ of  the FDA [30], method val-
idation included selectivity, linearity, accuracy, precision 
and stability. The linearity was assessed by using eight 
point calibration curves on three days for the three com-
pounds. To determine accuracy and precision, LLOQ, 
Low, Medium and High QC samples were analysed. All 
QC samples were analysed in fivefold in three separate 
runs on separate days. 
The calibration model was chosen by evaluating the ac-
curacy results at LLOQ, Low, Medium and High concen-
tration level of  the first precision and accuracy run.  The 
simplest linear model at three weighting factors (x, 1/x 
and 1/x2) at which all accuracies were within the speci-
fications of  the FDA was chosen and set for the entire 
validation and ensuing bioanalysis.
Automatic immuno-assays do not exist for the quantifi-
cation of  anti-TB drugs. Therefore, all assays for anti-TB 
drugs are ‘in-house’ developed and validated chromato-
graphic methods [31]. To be able to compare obtained 
results between laboratories, it is important to participate 
in an external quality control programme. Recently, such 
a proficiency testing programme has been set up [31] and 
we participated in the programme with the developed 
method. 
Matrix effect
The matrix effect was assessed using six different human 
sera and six different human edetate plasmas adding up 
to 12 different matrices. The first set (A) was prepared of  
QC stock in water to evaluate the neat MS response of  
the compounds and the internal standards. The second 
set (B), 12 different calibration sets were prepared with 
internal standard solution and after ultrafiltration QC 
stock was added. 
The matrix factor was calculated as the ratio of  the peak 
area of  the spiked standards after sample preparation (B) 
to the corresponding peak area of  the neat solution stan-
dards (A) [9]. The internal standard-normalised matrix 
factor was calculated by dividing matrix factor of  isonia-
zid and ethambutol by the matrix factor of  their internal 
standard [9]. As pyrazinamide was determined without 
internal standard, the matrix factor was calculated with-
out normalisation.
Stability
The stability of  the compounds was extensively evaluat-
ed as a part of  a larger investigation on the stability of  
many anti-TB drugs. Human serum standards were pre-
pared by adding appropriate amounts of  stock solution 
to blank matrices. Analyses were performed in duplicate 
and time point 0 served as the reference. The final serum 
concentrations for the Low concentration samples were 
0.51 mg/L isoniazid, 20.2 mg/L pyrazinamide and 1.00 
mg/L ethambutol. For the High concentration samples, 
the values were 6.89 mg/L, 62.4 mg/L and 5.09 mg/L 
for isoniazid, pyrazinamide and ethambutol respectively. 
The prepared human serum standards were divided into 
0.5 mL aliquots and stored in sealed plastic tubes at four 
different conditions: ambient temperature (18-24°C), re-
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(Fig. 1). Although isoniazid and ethambutol elute within 
a short period, no interference was observed. However, 
some tailing of  ethambutol was observed. We were un-
able to further diminish this tailing. 
The results of  the protein binding tests are presented in 
Table 4. As protein binding indeed proved to be low, 
ultrafiltration as a means of  sample preparation could be 
applied.
In the adsorption test, ethambutol showed a significant 
loss of  approximately 35% in peak area when injected 
from the standard glass vial (Fig. 2). The isoniazid re-
sponse showed a small but significant decrease when in-
jected from the polypropylene and the glass vial. Pyrazin-
amide was unaffected by the different materials. The type 
I borosilicate glass insert showed the least absorption for 
most compounds and was chosen as the standard vial.
The test for carry-over showed that it was caused by a 
memory effect of  the column. This memory effect was 
proven by repeating the gradient three times during an 
analytical run. During this experiment, isoniazid and eth-
ambutol peaks were observed at the interval of  the orig-
frigerator (4-8°C) and at two freezing temperatures (-20 
°C and -80°C). Frozen samples were thawed immediately 
before analysis. To determine bench top stability, samples 
were thawed and analysed immediately and after being 
left for 24 hours at ambient temperature. To determine 
the autosampler stability, Low and High QC samples 
were processed at day one, were left in the autosampler 
for 24 hours and re-injected on day two. 
To determine freeze/thaw stability, separate Low and 
High QC samples were thawed, frozen at -80°C and ana-
lysed on three consecutive days.
One portion of  human serum was divided into 1 mL al-
iquots in 10 mL glass containers and freeze-dried using a 
Leybold Lyovac GT4 lyophilizer according to local stan-
dard operating procedure by authorized personnel. Then 
they were sealed and refrigerated at 4-8°C. Freeze-dried 
samples were reconstituted by adding 1 mL of  water, im-
mediately before use. 
Clinical application
After validation the analytical procedure was used in 
routine patient care and a clinical study evaluating the 
influence of  food and fasting on the pharmacokinetics 
of  first-line anti-TB drugs. Twenty patients included in 
this study were diagnosed with drug susceptible TB and 
provided written informed consent. The study protocol 
was approved by the Medical and Health Research Ethics 




Using the Waters Atlantis T3 column, best peak shapes 
and repeatable retention times were obtained by starting 
and ending the mobile phase gradient in 100% aqueous 
conditions. Mean retention times were 1.15 min for eth-
ambutol, 1.41 min for isoniazid and 1.72 min for pyrazin-
amide, respectively (Table 1). The hold-up time of  the 
system is approximately 0.9 min. To optimize the chro-
matography of  the compounds a mobile phase buffer 
pH 5 was used. This resulted in acceptable peak shapes 
Figure 1. Chromatograms of  blank (dotted line) and LLOQ concen-
trations (solid line) of  ethambutol (0.2 mg/L), isoniazid (0.2 mg/L) 
and pyrazinamide (2.0 mg/L).
Table 3. Concentration of  stock solutions, calibration standards and QC samples.  
Compound Stock (mg/L) Calibration Standards (mg/L) QC samples (mg/L)
LLOQ Low Med High OTC
Isoniazid 200 0.2, 0.3, 0.5, 0.8, 1.5, 3.0, 5.0, 8.0 0.2 0.5 2.5 6.5 40
Pyrazinamide 2000 2.0, 3.0, 5.0, 8.0, 15, 30, 50, 80 2.0 5.0 25 65 400
Ethambutol 200 0.2, 0.3, 0.5, 0.8, 1.5, 3.0, 5.0, 8.0 0.2 0.5 2.5 6.5 400
QC: Quality Control, LLOQ: Lower Limit of  Quantification, OTC: over-the-curve
94
and <15% CV for the other QC samples. The maximum 
overall bias was 10.7% and the maximum overall CV was 
8.1%, which is well within the limits set by the FDA. 
We participated with this method in the second round of  
an interlaboratory quality control program for the mea-
surement of  anti-TB drugs [31]. All values were within 
the limits of  20% set by the organisation of  the pro-
gramme.
Matrix effect
The results for the matrix effect tests are listed in Ta-
ble 6. Data for both serum and plasma samples were 
pooled, as no significant difference was observed be-
tween them. For all compounds, a small positive (internal 
standard-normalised) matrix factor was determined for 
low and high concentrations. Maximum CV was 6.0% for 
the Low level of  ethambutol, this is within the limit of  
15% set by the EMA [9]. 
inal gradient. At every interval, peak areas were approxi-
mately 10% of  the preceding peak, for both isoniazid and 
ethambutol. This situation was similar to the carry-over 
our group observed during the quantification of  rifampin 
[15]. The memory effect was minimized to approximately 
0.1% by adding two flushing and conditioning steps to 
the original gradient, in which the column is flushed with 
100% eluent B and conditioned with 100% eluent A.
Analytical validation
Regarding selectivity, examination of  the six independent 
blank human serum or plasma samples revealed no in-
terfering components at the mass transitions monitored 
(Fig. 1). 
The validation results regarding accuracy and precision 
are listed in Table 5. Calibration curves for isoniazid and 
ethambutol were obtained by plotting the ratio of  peak 
area to that of  the internal standard against the concen-
tration. Pyrazinamide was not analysed using an internal 
standard because no stable isotope-labelled pyrazinamide 
was available. The calibration curves were fitted using 
least squares linear regression with a weighting factor of  
1/x. None of  the calibrators was discarded in the valida-
tion procedure. The calibration curves were linear in the 
range of  0.2-8 mg/L for isoniazid and ethambutol and 
2-80 mg/L for pyrazinamide. The average correlation 
coefficients were 0.9987 for isoniazid, 0.9992 for pyra-
zinamide and 0.9984 for ethambutol. All the calibration 
curves showed a significant goodness of  fit. All obtained 
results met the acceptance criteria set by the FDA [27]. 
These criteria were < 20% bias and <20% coefficient of  
variation (CV) for LLOQ QC samples and <15% bias 
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Table 4. Protein binding. 
Isoniazid Pyrazinamide Ethambutol
Slope water 226145 17732 2793786







Table 5. Accuracy and precision results. 
Concentration (mg/L) Bias (%) CV (%)
Isoniazid LLOQ (0.2) 10.7 6.7
Low (0.5) 2.2 2.5
Med (2.5) 4.3 8.1
High (6.5) 2.7 1.8
OTC (40.0) 7.1 3.3
Pyrazinamide LLOQ (2.0) -0.3 3.6
Low (5.0) -0.6 2.4
Med (25) 2.1 2.0
High (65) -4.5 1.7
OTC (400) -3.7 2.4
Ethambutol LLOQ (0.2) 7.3 5.9
Low (0.5) 2.3 3.3
Med (2.5) 2.6 2.2
High (6.5) 0.6 3.9
OTC (40.0) -10.5 3.9
LLOQ: Lower Limit of  Quantification, OTC:over-the-curve, CV: 
coefficient of  variation
Figure 2. Adsorption of  isoniazid, pyrazinamide and ethambutol to 
different materials. 
Stability
The results of  the stability tests showed that isoniazid is 
not stable at ambient temperature in human serum (Ta-
ble 7). However, if  it is present in ultra filtrate as in the 
autosampler test, isoniazid proves to be stable for at least 
24 h. Isoniazid serum standards are only stable at -80°C 
or in freeze-dried conditions for longer periods. From 
the data in Table 7, it is calculated that average in vitro 
half-life values for isoniazid were 6 days at ambient tem-
perature, 15 days at refrigerating temperatures and 115 
days at -20°C. 
None of  the three compounds in human serum showed 
degradation beyond criteria after three freezing and 
thawing cycles, although the concentrations of  the isoni-
azid and pyrazinamide samples at low concentration level 
dropped considerably after the third cycle.
Pyrazinamide in human serum is stable at all tempera-
tures except at ambient temperature. Measured pyrazin-
amide concentrations at ambient temperature started to 
decline significantly after five days. Since the human ma-
trices stored at ambient temperature showed signs of  de-
composition over time, degradation products may have 
affected these measurements. None of  the measured eth-
ambutol concentrations fell beyond acceptance limits at 
any of  the time points for all storage conditions. A limit-
ed concentration drop for all long term stability samples 
was observed however.
Clinical application
To illustrate the clinical application a concentration-time 
curve over a 24 h time period of  a TB patient recently 
started on TB treatment is shown in Fig. 3. She received 
her medication orally on an empty stomach. Including 
the preparation of  calibration standards and QC samples, 
it takes approximately 1.5 h to analyse the three drugs in 
these 12 samples. The maximum capacity is almost 200 
samples per 24 h. In the same time, the samples can be 
analysed for rifampin on a separate LC-MS/MS [7,15] 
resulting in a processing time similar to the method of  
Song [6]. 
Discussion
The most important aspect from these results presented 
here is that ethambutol did not show any significant in 
vitro protein binding in serum using this method, which 
clearly contradicts earlier results [17,20]. This may partly 
be caused by the difference in temperature, as this factor 
is known to influence protein binding [26]. In our experi-
ments we used an unthermostated centrifuge. However it 
can be observed from the accuracy and precision results 
in Table 5 that temperature had limited influence on the 
validation. In the adsorption test, ethambutol showed a 
significant loss of  approximately 35% in peak area when 
injected from the standard glass vial. Earlier reported 
protein binding results [17,20] vary and may be obscured 
by adsorption of  ethambutol to non deactivated glass 
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Isoniazid Low (0.5) 1.128 4.7
High (6.5) 1.157 5.0
Pyrazinamide* Low (5.0) 1.184 2.8
High (65) 1.142 3.3
Ethambutol Low (0.5) 1.079 6.0
Low (6.5) 1.065 5.5
*matrix factor of  pyrazinamide is not internal standard-normalised, 
due to absence of  stable isotope-labelled internal standard for pyra-
zinamide. CV: coefficient of  variation
Table 7. Stability testing results for isoniazid, pyrazinamide and ethambutol. 
Component Isoniazid Pyrazinamide Ethambutol
Sample Low (%) High (%) Low (%) High (%) Low (%) High (%)
Autosampler (ultra filtrate), 24h 96.7 97.4 97.1 98.5 92.9 93.7
Ambient temperature, 24 h 75.7 78.5 106.1 103.4 97.3 96.7
Ambient temperature, 51 d n.d. 28.2 n.d. 85.3 94.0 86.2
Refrigerator, 51 d 31.3 34.0 106.8 102.7 89.0 86.8
Freezer (-20°C), 51 d 74.2 67.8 99.7 109.6 84.6 90.4
Freezer (-80°C), 51 d 101.6 102.5 108.1 104.9 90.0 96.3
Freeze-dried, 51 d 101.6 95.6 104.9 103.8 82.0 87.8
Freeze-thaw (3 cycles) 87.0 94.4 86.6 98.2 111.7 103.3
n.d.: not detectable. Low sample: 0.51 mg/L isoniazid, 20.2 mg/L pyrazinamide and 1.00 mg/L ethambutol, High sample: 6.89 mg/L isonia-
zid, 62.4 mg/L pyrazinamide and 5.09 mg/L ethambutol. 
vials. Furthermore, any possible protein binding would 
be reduced by the extensive dilution of  the samples with 
internal standard solution during sample preparation 
before the ultrafiltration [32]. By then, variation of  any 
possible protein binding of  ethambutol in the diluted 
samples is compensated by the stable isotope-labelled in-
ternal standard. 
Protein binding of  isoniazid and pyrazinamide is also 
lower than reported values. Reported (reversible) protein 
binding values of  isoniazid might have been obscured by 
the instability of  isoniazid in serum. The instability of  
isoniazid is attributed to irreversible protein binding [33]. 
As protein binding of  isoniazid, pyrazinamide and eth-
ambutol proved low, ultrafiltration as a means of  sample 
preparation could be applied resulting in a fast and sim-
ple method of  analysis. 
Significant carry-over and memory effects were observed 
for isoniazid and ethambutol, during method develop-
ment. This can be explained by absorption to silica and 
metal surfaces, due to their polar characteristics. Car-
ry-over was overcome by rinsing the sample needle and 
needle seat with eluent B in-between sample injections. 
Memory effects were overcome by adding two flushing 
and conditioning steps to the original gradient (Table 2).
Bench-top stability testing and the more extensive sta-
bility assessment showed that isoniazid is unstable in hu-
man serum unless it is freeze-dried or stored at -80°C. 
Instability of  isoniazid in plasma at ambient temperature 
and -20ºC has been reported earlier [28,29]. This insta-
bility calls for adequate standard operating procedures 
and rapid handling of  samples. The autosampler stability 
testing show that isoniazid is stable in ultra filtrate for at 
least 24 hours proving that serum proteins are involved in 
the instability of  isoniazid. Pyrazinamide serum samples 
are more stable and can be kept for at least 51 days in a 
refrigerator. Ethambutol proved to be stable at ambient 
temperature. 
Using this method, almost 200 patient samples can be 
analysed for isoniazid, pyrazinamide and ethambutol in 
24 h. If  one makes use of  an optimal sampling strategy 
consisting of  three samples to calculate the area under 
the concentration-time curve, information on drug ex-
posure of  65 patients can be obtained in one day. The 
presented analytical method has shown to be robust for 
therapeutic drug monitoring and pharmacokinetic stud-
ies of  isoniazid, pyrazinamide and ethambutol. It may be 
of  clinical help and importance as the current opinion is 
moving from standard dosing towards a more drug expo-
sure based evaluation of  TB treatment [34]. 
Conclusion
A fast, simple and reliable LC-MS/MS method has been 
developed for the determination of  isoniazid, pyrazin-
amide and ethambutol in human serum. Isoniazid, pyr-
azinamide and especially ethambutol have proven to be 
low protein bound. Therefore, ultrafiltration as a means 
of  sample preparation could be applied. The method ad-
heres to all the validation criteria and is suitable for the 
simultaneous determination of  isoniazid, pyrazinamide 
and ethambutol in human serum for therapeutic drug 
monitoring and pharmacokinetic studies.
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